Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPX-121 safety in nasolabial folds
NCT06533540Phase 1Active, not recruiting
- Sponsor
- Tego Science
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TPX-115 in nasolabial folds (3 arms), sponsored by Tego Science. Primary endpoint: Dose-limiting toxicity at Week 4. Started Dec 2024; status: active, not recruiting.
02
Drugs
TPX-115
03
Conditions
nasolabial folds
Beyond the preview
Go deeper on NCT06533540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533540.